Robert Medaer
About
In The Last Decade
Robert Medaer
22 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 75
- Immunology 1.1k
- Pathology and Forensic Medicine 616
- Molecular Biology 167
- Oncology 163
- Rheumatology 138
Countries citing papers authored by Robert Medaer
This map shows the geographic impact of Robert Medaer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Medaer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Medaer more than expected).
Fields of papers citing papers by Robert Medaer
This network shows the impact of papers produced by Robert Medaer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Medaer. The network helps show where Robert Medaer may publish in the future.
Co-authorship network of co-authors of Robert Medaer
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Medaer. A scholar is included among the top collaborators of Robert Medaer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Medaer. Robert Medaer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 41 | |
| 2 | 47 | |
| 3 | Compromised CD4+CD25Hi regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3 positive cells and a reduced FOXP3 expression at the single-cell level | 0 |
| 4 | 293 | |
| 5 | Secondary progressive in contrast to relapsing: remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T cell function and FOXP3 expression | 7 |
| 6 | 153 | |
| 7 | 43 | |
| 8 | 10 | |
| 9 | 41 | |
| 10 | 109 | |
| 11 | 32 | |
| 12 | The multiple sclerosis PRISMS study: Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis | 2 |
| 13 | 1 | |
| 14 | 5 | |
| 15 | 21 | |
| 16 | 100 | |
| 17 | 83 | |
| 18 | 230 | |
| 19 | 129 | |
| 20 | 9 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.